Second Genome is a clinical stage pharmaceutical company with a mission to redefine disease in the context of microbiome medicine. We leverage our proprietary drug discovery platform to identify effective peptides, proteins and small molecule therapeutics that can address unmet medical needs.
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by integrating computational science, machine learning with human disease biology to redefine diseases, and generate libraries of compounds that are screened in traditional drug discovery and development assays.
Our lead clinical program, SGM-1019, targets inflammatory pathways identified in both NASH and IBD, offering the potential for a novel, safe and well-tolerated oral therapy for the treatment of these diseases.